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Current treatments for hair follicle (HF) disruption are based on 5-a reductase inhibitors and 
prostaglandin modulators. Botanicals and nutraceutical compounds interfere with hair loss or 
stimulate its partial regrowth. Here we used in vitro cocultures to investigate the activity of 
Serenoa repens (SR) and N-Acetyl Glucosamine+milk proteins (NAG/Lac) on the paracrine 
interactions between human microvascular endothelial cells (HMVEC) and HF dermal 
papilla cells (FDPC). Both SR and NAG/Lac-induced endothelial tubulogenesis were 
enhanced by FDPC. SR promoted proliferation of both the cell types, while NAG/Lac was 
effective on endothelium. VEGF production, enhanced by SR, was further augmented by 
FDPC. In FDPC 5-a reductase-II and b-catenin expressions were modified by SR and less by 
NAG/Lac, with no additional effect by HMVEC. SR and NAG/Lac prevented lipid 
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peroxidation, whereas NAG/Lac was effective on IL-1b production. Finally, SR and  
NAG/Lac differentially affected HMVEC permeability and tight junction proteins content. 
These data provide a mechanistic background for the potential use of these compounds as 







The dermal papilla is a cluster of mesenchymal cells located at the base of the hair follicle 
(HF) which have a number of important roles in the regulation of hair growth (Topouzi et al., 
2017). HF dermal papilla controls hair growth and is characterized in the anagen phase by a 
highly developed vascular network with enhanced expression of angiogenic growth factors 
and cytokines (Yano et al., 2001). Nutritional deficiency may impact both hair structure and 
hair growth. Effects on hair growth include acute telogen effluvium (TE), a well-known 
effect of sudden weight loss or decreased protein intake (Mubki 2014). Other studies reported 
a potential association between nutritional deficiency and chronic telogen effluvium, 
Androgenetic alopecia (AGA), female pattern hair loss (FPHL), and Alopecia areata (Guo, 
Katta 2017). Clinical observations, as well as animal studies and in vitro techniques have 
been developed to investigate and promote hair reconstitution (Ohyama, Veraitch 2013). 
Recently, new therapeutical options with topical 5-a reductase inhibitors, prostaglandin 
modulators, and treatments with stem cells have been proposed in order to overcome the 
limitations of oral finasteride and topical minoxidil (MXD), the current gold standard for 
AGA treatment (Valente Duarte de Sousa, Tosti 2013). 
A number of botanicals or dietary supplements are available that can effectively slow or 
reduce hair loss and inflammation observed in AGA or stimulate partial hair regrowth 
(Rondanelli et al., 2016; Prager et al., 2006). Serenoa repens (SR) is a low-growing palm tree 
that is endemic to all counties of Florida, (USA). Permixon, a pharmaceutical extract from 
fruit SR, is anti-androgenic and has been used to relieve symptoms of benign prostate 
hyperplasia (Ooi Pak 2017). SR is one among the many naturally occurring 5-a-reductase 
inhibitors which has gained popularity as a remedy for AGA (Murugusundram 2009). 
Liposterolic extract of SR (LSESr) and its glycoside, β-sitosterol, were tested in subjects with 
AGA which showed a highly positive response to treatment. The blockade of inflammation 
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using a composition containing LSESr as well as two anti-inflammatory agents (carnitine and 
thioctic acid) alters the expression of molecular markers of inflammation in in vitro system. 
These findings suggest that 5-a reductase inhibitors combined with blockade of inflammatory 
processes could represent a novel two-pronged approach in the treatment of AGA with 
improved efficacy over current modalities (Chittur et al., 2011). Notably, in vitro assays 
revealed the ability of LSESr to inhibit 5-alpha-reductase expression 3-fold better than 
Finasteride (Chittur et al., 2011). Recently, SR has been proposed as a ‘natural’ alternative to 
conventional treatments for male AGA as well as for other hair disorders (Wessagowit et al., 
2016).  
In this work we compare the effects of SR to a mixture of N-acetyl-Glucosamine (NAG) and 
milk proteins (b-Lactoglobulin + a-Lactalbumin) (Lac). The precursor for Hyaluronic Acid, 
NAG, is a hexosamine sugar that is metabolized by the hexosamine biosynthesis pathway and 
stimulates O-linked N-acetyl-glucosamine (O-GlcNAc) modification (O-GlcNAcylation) of 
cytosolic and nuclear proteins (DeAngelis et al., 2013). Clinical tests of formulations 
containing NAG have shown that it can also reduce the appearance of facial 
hyperpigmentation, especially when used beside niacinamide (Sarkar et al., 2013). Due to the 
versatile functions of Glucosamine and its derivative NAG, they are considered valuable 
ingredients for accelerating wound healing, improving skin hydration, and decreasing 
wrinkles and colors (Bisset et al., 2007; Vournakis et al., 2008). Interestingly, poly-N-acetyl 
glucosamine nanofibers have been recently reported to regulate endothelial cell migration 
leading to angiogenesis (Vournakis et al., 2008). The hair apparatus contains considerable 
amounts of complex carbohydrates with different saccharide residues (alpha-D-mannose, 
beta-D-glucose, alpha-L-fucose and NAG). Moreover, the presence of glycogen in outer root 
sheath cells might enable these cells to provide other hair cells with energy when necessary 
(Ishii et al., 2001). 
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Milk is considered one of the most nutritionally complete foods available, it is mainly 
composed of water, lipids, lactose and proteins, and their relative shares widely vary among 
species (Kuligowski et al., 2017). The two most prominent and abundant proteins of whey 
protein fraction are β-lactoglobulin and α-lactalbumin (Li et al., 2017). b-Lactoglobulin is the 
major whey protein in ruminant species; for its amino-acid sequence and 3D structure it 
belongs to lipocalins, a widely diverse family of proteins, most of which bind small 
hydrophobic ligands and thus may act as specific transporters, similar to serum retinol 
binding protein (Brownlow et al., 1997). In addition, b-Lactoglobulin from buffalo colostrum 
inhibits cell proliferation, micro-vessel sprouting, cell migration and tube formation of human 
umbilical vein endothelial cells (Chougule et al., 2013). A recent study reported the ability of 
Gly-Leu-Phe (GLF), an immune-stimulating peptide derived from a-lactalbumin, to prevent 
alopecia induced by the anticancer agent etoposide in a neonatal rat model after 
intraperitoneal injection (Tsuruki  et al., 2005).  
We previously established transwell-based cocultures to show that FDPC promote viability, 
proliferation and tubulogenesis of HMVEC, as well as to test the effects of biomimetic 
peptide Sh-Polypeptide 9 (CG-VEGF) (Bassino et al., 2015, 2016). Here we took advantage 






MATERIALS AND METHODS  
Compounds 
Serenoa repens (SR) (Euromed S.A. BARCELONA (SPAIN), N-Acetyl Glucosamine (NAG) 
(Polichimica Srl Bologna Italia), milk proteins (b-Lactoglobulins + a-Lactalbumin: Lac) 
(DAVISKO FOODS INTERNATIONAL Inc. USA) (milk proteins: 75% b-Lactoglobulins 
and 22.03% a-Lactalbumin, NAG/milk proteins ratio: 1:1) were used at different 
concentrations (2.5 mg/ml, 25 µg/ml and 2.5 µg/ml).  
 
Cell Culture 
Human hair follicle dermal papilla cells (FDPC) were obtained from PromoCell (Germany; 
lot 2040301.35). FDPC were grown in Follicle Dermal Papilla Cell Medium (PromoCell) 
with 1% antibiotic/antimycotic (Invitrogen, Grand Island, NY, USA). In order to avoid 
phenotypical changes occurring during cell culture, only FDPC at 2-7 passages were used for 
all experiments. Human microvascular endothelial cell line (HMVEC) was purchased from 
Lonza and grown in EGM 2-MV medium (Lonza, Basel, Switzerland). All cell types were 
maintained at 37°C in a humidified atmosphere of 5% CO2.   
 
Cocultures 
HMVEC were thawed from frozen stock and seeded in 24 well plates at a density of 2.5 x 103 
cells/well, medium was discarded after 18 hrs, then complete medium was replaced with 
DMEM 2% FCS to reduce cell proliferation for 24 hrs and finally replaced with DMEM 0% 
+ compounds (NAG/Lac or SR, used at different concentrations) alone or in the presence of 
the insert with FDPC. For cell proliferation in coculture, FDPC were thawed, centrifuged, 
recounted and seeded at a density of 2.5 x 103 cells/well for 2 days in Dulbecco's Modified 
Eagle Medium (DMEM) + 10% Fetal Calf Serum (FCS) until 100% confluence on Transwell 
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clear polyester membrane inserts with 0.4-um pore size and a 0.3-cm2 area (Corning). The 
proliferation of HMVEC (alone or in the presence of FDPC on the insert) was analyzed after 
24 hrs of coculture. As described above for FDPC, HMVEC were seeded on the Transwell 
clear polyester membrane inserts and exposed to the same experimental protocol.  
 
Cell viability  
For proliferation assays in cocultures, HMVEC or FDPC (2.5 x 103 cells/well) were seeded in 
24-well plates following the protocols described in the previous chapter. Cell number was 
evaluated by the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
(Promega, Madison, WI, USA), using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt (MTS). MTS 
conversion into the aqueous soluble formazan product is accomplished by dehydrogenase 
enzymes found in metabolically active cells. Formazan product was measured with a F5 
FilterMax microplate reader (Molecular Devices, Sunnyvale, CA, US) at 490 nm, as 
absorbance is directly proportional to the number of viable cells. 
 
Tubulogenesis 
Matrigel (Collaborative Biomedical Products, USA) was used to make up a basement 
membrane matrix gel solution for cell suspension. Sub-confluent HMVEC were trypsinized 
and 5.0×104 cells were added to each well of a chilled 24-well plate and allowed to gel for 30 
min at 37°C in a humidified 5% CO2 atmosphere. HMVEC, with or without insert containing 
FDPC at the different experimental conditions, were maintained in a stable humidified 5% 
CO2 atmosphere for all the experimental time course (18 hrs). Image acquisition and 
statistical analysis were performed with Metafluor and ImageJ softwares, respectively. 
Tubulogenic indexes were obtained with Angiotool software and include total vessel length 
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and total number of junctions.  
 
ELISA Assays 
b-catenin, VEGF, Occludin, Claudin-5 and IL-1b (in cell lysates or medium) were assessed 
by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (Sigma 
ELISA Kit). Briefly, 100µL of medium (for VEGF and IL-1b) or cell lysate (for occludin, and 
nuclear cell lysate for b-catenin; See below ‘Nuclear protein extraction for b-catenin 
quantification’) were incubated into an antibody-coated 96-well plate at room temperature for 
2.5 hrs. The wells were washed four times with wash buffer solution. Then 100 µL anti-
human b-catenin or IL-1a antibody was added and the samples were again incubated for 1h 
at room temperature. The plate was washed four times, 100µL of streptavidin-peroxidase 
conjugated was applied for 1h at room temperature. After a final washing, 100 µL 
tetramethylbenzidine substrate was added and allowed to develop for 30 min in the dark at 
room temperature. After stopping the reaction with 50 µL stop solution containing citric acid 
2.0 mmolL-1, absorbance was read at 450 nm using a F5 FilterMax microplate reader 
(Molecular Devices, Sunnyvale, CA, US). Sample concentration was calculated from the 
standard curve.  
 
Nuclear protein extraction for b-catenin quantification 
FDPC were grown to 70-80% confluence. Afterwards, cells were scraped using fresh PBS, 
collected into an appropriate conical tube and centrifuged (5 min at 450 x g). Then the 
supernatant was discarded and 1 mL Lysis Buffer (10 mM Tris HCl, pH 7.5, 2 mM MgCl2, 3 
mM CaCl2, 0.3 M Sucrose, including DTT and protease inhibitors) added to 200 µL of 
packed cell volume (PCV) for 15 min. Suspended cells were centrifuged for 5 minutes at 420 
x g. Pellet of packed cells was resuspended in 400 µL (2X PCV) of Lysis Buffer and 
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fragmented using a syringe with a narrow-gauge. The disrupted cells in suspension were 
centrifuged for 20 min at 10,000 x g. The supernatant was transferred into a fresh tube and 
this fraction corresponds to the cytoplasmic fraction. Subsequently the pellet was 
resuspended in 140 µl of extraction buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl2, 
0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) Glycerol added with 1.5 µL of the 0.1 M DTT 
solution and 1.5 µL of the Protease Inhibitor Cocktail) and centrifuged for 5 min at 20,000 x 
g. The resulting supernatant is the nuclear protein extract. It is finally collected to a clean tube 
and analyzed with b-catenin ELISA assay.   
 
Fluorescence microscopy 
5-a reductase II expression was detected using immunofluorescence assay. Briefly, after the 
treatments cells were fixed in 4% paraformaldehyde for 25 min at room temperature. Then, 
the fixed cells were washed three times with ice cold PBS solution, incubated 20′ with 0.3% 
Triton, and 1% bovine serum albumin (BSA, Sigma, St. Louis, MO) in PBS, and stained with 
the primary antibody 24 hrs at 4°C. Cover slides were washed twice with PBS and incubated 
1h at room temperature with the secondary antibody. After two washes in PBS, cover slides 
were mounted on standard slides with DABCO (Sigma) and observed after 24 hrs with by 
fluorescence microscopy (Nikon T-E microscope, 10×objective). For each experiment, we 
randomly acquired three fields/sample evaluating the mean of fluorescence intensity/cell/field 
(about 30 cells/field).  
 
Lipid peroxidation 
Lipid peroxidation (LP) was analyzed using Click-iT® LAA reaction kit (LifeTechologies). 
Briefly, Linoleic acid is the most abundant polyunsaturated fatty acid found in mammals and 
its LP products likely account for the majority of lipid-derived protein carbonyls. When 
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incubated with cells, LAA (Linoleamide alkyne) incorporates into cellular membranes. Upon 
LP, LAA is oxidized and produces 9- and 13-hydroperoxy-octadecadienoic acid (HPODE). 
These hydroperoxides decompose to multiple α, β-unsaturated aldehydes, which readily 
modify proteins at nucleophilic side chains. These alkyne-containing modified proteins can 
be subsequently detected using Click-iT® chemistry and multiplexed with other probes 
appropriate for fixed cells. Briefly, HMVEC were grown and recovered overnight at 37°C 
alone or with FDPC and treated with H2O2 used alone or with NAG/Lac or SR, respectively. 
Then we added Click-iT® LAA stock solution to the cells in complete growth medium at a 
final concentration of 50 µM and we treated the cells with the compound of interest for the 
desired time. Cells were washed three times with PBS to remove free Click-iT® LAA from 
the cells, and immediately fixed and permeabilized. Finally we added 0.5 mL of Click-iT® 
reaction cocktail to each well containing a coverslip. Cells were incubated for 30’ at room 
temperature, protected from light. Fluorescence (Alexa Fluor® 488) was acquired using a F5 
FilterMax microplate reader (excitation emission maxima: 495/519nm) (Molecular Devices, 
Sunnyvale, CA, US).  
 
Transendothelial Resistance (TEER) measurement 
The transendothelial resistance (inverse of permeability) of HMVEC monolayer treated with 
the different compounds was evaluated with TEER measurements, using an Endohm 12 
electrode chamber and an endothelial volt/ohm meter EVOM2 (World precision Instruments, 
USA). TEER values were obtained from three independent experiments.  
 
Statistical analysis  
Statistical significance in all experiments was evaluated by Kaleidagraph software (Synergy 
Software, USA) using nonparametric Wilcoxon test. The Wilcoxon test was chosen for the 
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survival assays analysis because for each condition in each experiment five biological 
replicates were done and they were not normally distributed. The Wilcoxon test was also used 
for cell tubulogenesis analysis because the percentages of tubulogenesis were not normally 
distributed. All values are presented as the mean ± standard error (SEM). For each 
experimental condition five technical replicates were performed; three biological replicates 
were done for each experiment: N=3. Results with p-values < 0.05 were considered 






















Effects of SR and NAG/Lac on tubulogenesis and VEGF production by HMVEC grown alone 
or cocultured with FDPC. 
SR enhanced HMVEC tubulogenic potential measured by endothelial tube formation assay 
both in terms of total tubule length and number of junctions (Fig. 1B-F, see Fig. 1A for set-up 
configurations); FDPC significantly increased both tubulogenic indexes only in presence of 
the highest dose of SR (Fig. 1, see Fig. 1A for set-up configurations). All concentrations of 
NAG/Lac enhanced HMVEC tubulogenic indexes (Fig. 1B-F, see Fig. 1A for set-up 
configurations), although the effect was more prominent for the highest dose of NAG/Lac 
(2.5mg/ml).  
The presence of FDPC further increased tubulogenic indexes, the effect was statistically 
significant only for the lowest dose (Fig. 1B-F). Accordingly, SR and NAG/Lac were both 
able to significantly promote VEGF production from endothelial cells; coculture with FDPC 
produced a significant additional enhancement only upon SR treatment (Fig. 1G).  
 
SR and NAG/Lac affect proliferation of HMVEC and FDPC grown separately or in coculture. 
NAG/Lac (25µg/ml) promoted proliferation of FDPC grown alone, without any additional 
effect of the coculture with HMVEC (Fig. 2B, see Fig. 2A for set-up configurations). All 
concentrations of SR significantly increased FDPC number (Fig. 2B). The presence of 
HMVEC, in coculture configuration, significantly enhanced the response of 25µg/ml SR (Fig. 
2B). NAG/Lac significantly increased cell number of HMVEC grown alone, and the 
coculture with FDPC further enhanced the response in presence of 2.5µg/ml NAG/Lac (Fig. 
2C). All concentrations of SR promoted HMVEC proliferation (Fig. 2C). An additional gain 




Effects of SR and NAG/Lac on the expression of 5-a reductase II and b-catenin by FDPC. 
The 5-a reductase II enzyme catalyzes the conversion of testosterone to dihydrotestosterone 
(DHT), the most potent male hormone that causes AGA (Jang et al., 2007). Here, we tested 
the role of both compounds in the modulation of 5-a reductase II expression in testosterone 
treated cells. As indicated by the graph, in coculture configuration, HMVEC drastically 
reduced 5-a reductase II expression in FDPC treated with testosterone. SR significantly 
prevented 5-a reductase II expression triggered by 100 nM testosterone in FDPC (Fig. 3A, B 
(i, ii)) (24 hrs). NAG/Lac completely failed to counteract the response to testosterone.  
Moreover, SR increased the nuclear expression of b-catenin in FDPC with no further 
variations in coculture with the endothelium. Conversely, NAG/Lac was ineffective on b-
catenin expression in FDPC; the presence of HMVEC raised this parameter only in the 
presence of NAG/Lac (2.5mg/ml) (Fig. 3C).  
 
Effects of SR and NAG/Lac on IL-1b production and lipid peroxidation by HMVEC alone or 
in coculture with FDPC.  
We asked whether SR and NAG/Lac could protect endothelium against oxidative stress 
typically occurring during aging, skin wounding and inflammation. HMVEC were treated 
with H2O2 (400µM, 24 hrs) to induce a strong oxidative stress. 400µM H2O2 strongly induced 
endothelial lipid peroxidation (LP) (Fig. 3D). The FDPC-derived CM significantly prevented 
LP (Fig. 3D). NAG/Lac and SR drastically reduced oxidative stress, but the presence of 
FDPC-derived CM abolished SR effect (Fig. 3D). NAG/Lac also prevented IL-1b production 
by HMVEC treated with H2O2 and in presence of FDPC. No changes were observed when 





SR and NAG/Lac modify endothelial permeability: evaluation of TEER and tight junction 
protein content. 
HMVEC were grown at confluence and TEER measurements were performed for 7 days 
(Fig. 4A). As indicated by the graph, the highest concentration (2.5mg/ml) of SR and 
NAG/Lac reduced endothelial resistance upon 24 hrs of treatment. The TEER values did not 
recover up to 96 hrs of treatment. Accordingly, NAG/Lac decreased the content of Occludin, 
a well-known component of the tight junctions (24 hrs), while no variations were induced by 
SR treatment (Fig. 4B). Finally, both compounds reduced the cytosolic levels of Claudin-5, 
another protein included in tight junctions (24 hrs), although the effect was statistically 



































We recently reported that human follicle dermal cells strongly support endothelial survival, 
proliferation and tubulogenesis in transwell cocultures (Bassino et al., 2015). Here the same 
approach was employed to investigate the activity of nutritional supplements. Recently, has 
been reported that the diet supplementation with omega -3 and -6 and antioxidants acts 
efficiently against female hair loss in improving hair density and reducing the telogen 
percentage and the proportion of miniaturized anagen hair (Le Floc’h et al., 2014). In this 
work we tested the role of SR and NAG/Lac compounds in the regulation of the paracrine 
cross-talk between endothelium and follicle dermal papilla cells. Here, we show that SR and 
NAG/Lac exert differential activities. In particular, the results reveal that SR is more powerful 
than NAG/Lac in promoting endothelial production of VEGF and tubulogenesis; notably, the 
activity of SR is more effective than previously measured for the widely used topical drug 
minoxidil (see Bassino et al., 2016). SR enhances b-catenin expression by FDPC, protects 
vascular endothelium from oxidative stress and prevents 5-a reductase II expression induced 
by testosterone. Recently, the topical application of SR extract was suggested to be an 
alternative treatment in male patients who cannot tolerate the side-effects of standard 
medications (Wessagowit et al., 2016). Specifically, the lipido- sterolic extract of SR, LSESr, 
highly enriched with fatty acids and phytosterols, was reported to block both isoforms of 5-a 
reductase (types I and II) in contrast to finasteride (Chittur et al., 2011). Moreover, LSESr 
promotes hair regeneration and repair in mouse models by activating TGF-β signaling and 
mitochondrial pathway (Zhu et al., 2018). Finally, we observed that both compounds affect 
endothelial permeability ad alter the expression of occludin and claudin-5, two critical 
components of the tight junction complexes. These results unveil a novel functional role for 
SR and NAG/Lac that could efficiently lower vascular endothelium resistance. In conclusion, 
our in vitro study points to SR an NAG/Lac as effective compounds; nonetheless, further 
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mechanistic studies, strengthened by in vivo and clinical trials, are required to shed more light 
on their applicative potentiality. 
 
Acknowledgements 
E.B. designed the research study, performed the research, analyzed the data and wrote the 
paper. 
F.G. designed the research study and contributed essential reagents. 
L.M. designed the research study, wrote the paper and contributed essential reagents. 




1. Topouzi H, Logan NJ, Williams G, Higgins CA. 2017. Methods for the isolation 
and 3D culture of dermal papilla cells from human hair follicles. Exp Dermatol. 
26, 491-496.  
2. Yano K, Brown LF, Detmar M. 2001. Control of hair growth and follicle size by 
VEGF-mediated angiogenesis. J Clin Invest. 107, 409-17 
3. Mubki T. 2014. Use of Vitamins and Minerals in the Treatment of Hair Loss: A 
Cross-Sectional Survey among Dermatologists in Saudi Arabia. J Cutan Med 
Surg. 18, 405-12.  
4. Guo EL, Katta R. 2017. Diet and hair loss: effects of nutrient deficiency and 
supplement use.  Dermatol Pract Concept. 7,1-10. 
5. Ohyama M, Veraitch O. 2013. Strategies to enhance epithelial-mesenchymal 
interactions for human hair follicle bioengineering. J Dermatol Sci.70,78-87. 
6. Valente Duarte de Sousa IC, Tosti A. 2013. New investigational drugs for 
androgenetic alopecia. Expert Opin Investig Drugs. 22, 573-89.  
7. Rondanelli M, Perna S, Peroni G, Guido D. 2016. A bibliometric study of 
scientific literature in Scopus on botanicals for treatment of androgenetic alopecia. 
J Cosmet Dermatol. 2,120-30.  
8. Prager N, Bickett K, French N, Marcovici GA. 2006. Randomized, double-blind, 
placebo-controlled trial to determine the effectiveness of botanically derived 
inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern 
Complement Med. 8,143-52. 
9. Ooi SL, Pak SC. 2017. Serenoa repens for Lower Urinary Tract 
Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical 
Implications in Naturopathic Medicine. J Altern Complement Med. 8, 599-606. 
10. Murugusundram S.  2009. Serenoa Repens: Does It have Any Role in the 
Management of Androgenetic Alopecia? J Cutan Aesthet Surg. 1,31-2. 
11. Chittur S, Parr B, Marcovici G. 2011. Inhibition of inflammatory gene expression 
in keratinocytes using a composition containing carnitine, thioctic Acid and saw 
palmetto extract. Evid Based Complement Alternat Med. 2011, 985345. 
12. Wessagowit V, Tangjaturonrusamee C, Kootiratrakarn T, Bunnag T, Pimonrat T, 
Muangdang N, Pichai P. 2016. Treatment of male androgenetic alopecia with 
17 
 
topical products containing Serenoa repens extract. Australas J Dermatol. 57, 76-
82. 
13. DeAngelis PL, Liu J, Linhardt RJ. 2013. Chemoenzymatic synthesis of 
glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or 
most complex carbohydrate chains. Glycobiology. 23,764-77. 
14. Sarkar R, Arora P, Garg KV. 2013. Cosmeceuticals for Hyperpigmentation: What 
is Available? J Cutan Aesthet Surg. 6,4-11. 
15. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki Jim Li T, Kelm 
GR. 2007. Reduction in the appearance of facial hyperpigmentation by topical N-
acetyl glucosamine. Journal of Cosmetic Dermatology. 6, 20–26.  
16. Vournakis JN, Eldridge J, Demcheva M, Muise-Helmericks RC. 2008. Poly-N-
acetyl glucosamine nanofibers regulate endothelial cell movement and 
angiogenesis: dependency on integrin activation of Ets1. J Vasc Res. 45, 222-32. 
17. Ishii M, Tsukise A, Meyer W. 2001. Lectin histochemistry of glycoconjugates in 
the feline hair follicle and hair. Ann Anat. 183, 449-58. 
18. Kuligowski J, Schwaighofer A, Alcaráz MR, Quintás G, Mayer H, Vento M, 
Lendl B. 2017. External cavity-quantum cascade laser (EC-QCL) spectroscopy for 
protein analysis in bovine milk. Anal Chim Acta. 963, 99-105. 
19. Li Z, Wen F, Li Z, Zheng N, Jiang J, Xu D. 2017. Simultaneous detection of α-
Lactoalbumin, β-Lactoglobulin and Lactoferrin in milk by Visualized Microarray. 
BMC Biotechnol. 17,72. 
20. Sharon Brownlow, João H Morais Cabral,  Ron Cooper, Darren R Flower, Stephen 
J Yewdall, Igor Polikarpov, Anthony CT North, Lindsay Sawyer. 1997. Bovine β-
lactoglobulin at 1.8 Å resolution -  still an enigmatic lipocalin. Cell press. 15, 481-
495. 
21. Chougule RA, P S, Salimath BP, Sosalegowda AH. 2013. Buffalo colostrum β-
lactoglobulin inhibits VEGF-induced angiogenesis by interacting with G protein-
coupled receptor kinase. Appl Biochem Biotechnol. 171, 366-81.  
22. Tsuruki T, Yoshikawa M. 2005. Anti-alopecia effect of Gly-Leu-Phe, an 
immunostimulating peptide derived from α-lactalbumin. Biosci Biotechnol 
Biochem. 69, 1633–5. 
23. Bassino E, Gasparri F, Giannini V, Munaron L. 2015. Paracrine cross-talk between 
human hair follicle dermal papilla cells and microvascular endothelial cells. Exp 
Dermatol. 24, 388-90. 
24. Bassino E, Zanardi A, Gasparri F, Munaron L. 2016. Effects of the biomimetic 
peptide Sh-Polypeptide 9 (CG-VEGF) on cocultures of human hair follicle dermal 
papilla cells and microvascular endothelial cells.  Exp Dermatol. 25, 237-9. 
25. Jang S, Lee Y, Hwang SL, Lee MH, Park SJ, Lee IH, Kang S, Roh SS, Seo YJ, 
Park JK, Lee JH, Kim CD.  2007. Establishment of type II 5alpha-reductase over-
expressing cell line as an inhibitor screening model. J Steroid Biochem Mol Biol. 
107:245-52. 
26. Le Floc'h C, Cheniti A, Connétable S, Piccardi N, Vincenzi C, Tosti A. 2015. 
Effect of a nutritional supplement on hair loss in women. J Cosmet Dermatol. 
14,76-82.  
27. Wessagowit V, Tangjaturonrusamee C, Kootiratrakarn T, Bunnag T, Pimonrat T, 
Muangdang N, Pichai P. 2016. Treatment of male androgenetic alopecia with 




28. Zhu HL, Gao YH, Yang JQ, Li JB, Gao J. 2018. Serenoa repens extracts promote 
hair regeneration and repair of hair loss mouse models by activating TGF-β and 
mitochondrial signaling pathway. Eur Rev Med Pharmacol Sci. 22:4000-4008. 
 
FIGURE LEGENDS 
Figure 1. SR and NAG/Lac promote tubulogenesis and VEGF production by HMVEC. 
A) Scheme of the experimental setup and relative contrast phase images of tubule formation 
at 18hrs. Arabic numbers (1-5) are referred to the mono-culture and coculture configurations. 
1) HMVEC in DMEM 10% or HMVEC in DMEM 10% + FDPC; 2) HMVEC in DMEM 
10% + NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml); 3) HMVEC in DMEM 10% + SR 
(2.5mg/ml, 25µg/ml and 2.5µg/ml); 4) HMVEC in DMEM 10% + NAG/Lac (2.5mg/ml, 
25µg/ml and 2.5µg/ml) and in presence of FDPC; 5) HMVEC in DMEM 10% + SR 
(2.5mg/ml, 25µg/ml and 2.5µg/ml) and in presence of FDPC. 
B) Total number of junctions were evaluated in HMVEC (grown alone or cocultured with 
FDPC) treated with SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml).  
C) Total tubule length was analyzed on HMVEC (grown alone or in coculture with FDPC) 
treated with SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml). 
D) VEGF quantification in HMVEC (grown alone or cocultured with FDPC) treated with SR 
and NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml).   
 
Figure 2. SR and NAG/Lac promotes proliferation.  
A) Scheme of the experimental setup. Arabic numbers (1-4) are referred to the mono-
culture and coculture configurations. 1) FDPC or HMVEC in DMEM 10%; 2) FDPC or 
HMVEC in DMEM 0% + SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml); 3) HMVEC in 
coculture with FDPC + SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml); 4) FDPC in 
coculture with HMVEC + SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml). 
B) Cell proliferation (24 hrs) of FDPC grown alone or in coculture with HMVEC and in 
presence of SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml). 
C) Cell proliferation (24 hrs) of HMVEC grown alone or in coculture with FDPC and in 
presence of SR or NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml). 
 
Figure 3. SR and NAG/Lac differently affect 5-a reductase II, b-catenin expression and pro-
inflammatory processes.  
A) Scheme of the experimental setup. Arabic numbers (1-4) are referred to the monoculture 
and coculture configurations. 1) FDPC + testosterone (100nM) or H2O2 (400µM) and 
treated with NAG/Lac (2.5mg/ml); 2) FDPC were grown in presence of CM of HMVEC 
+ testosterone (100nM) or H2O2 (400µM) and treated with the NAG/Lac (2.5mg/ml); 3) 
FDPC + testosterone (100nM) or H2O2 (400µM) and treated with SR (2.5mg/ml); 4) 
FDPC were grown in presence of CM of HMVEC + testosterone (100nM) or H2O2 
(400µM) and treated with SR (2.5mg/ml). 
B) Representative images of FDPC grown alone or in coculture with HMVEC + 100nM 
testosterone and NAG/Lac or SR (2.5mg/ml). Images of 5-a reductase-II fluorescence 
intensity were taken with Olympus fluorescence microscope after 24hrs of treatment (i). 
Statistical analysis of 5-a reductase-II fluorescence intensity (F.I.) (ii).  
C) b-catenin quantification in FDPC grown alone or in coculture with HMVEC + SR or  
NAG/Lac (2.5mg/ml, 25µg/ml and 2.5µg/ml).   
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D) Lipid peroxidation in HMVEC (treated with H2O2)  grown alone or in presence of FDPC 
+ SR or NAG/Lac (2.5mg/ml).  
E) IL-1b production in HMVEC (treated with H2O2) grown alone or in presence of CM of 
FDPC + SR or NAG/Lac (2.5mg/ml). 
 
 
Figure 4. SR and NAG/Lac affect endothelial permeability of HMVEC monolayer and tight 
junctions content.  
A) TEER measurement in HMVEC treated for 7 days with NAG/Lac (2.5mg/ml) and SR 
(2.5mg/ml). 
B) Occludin quantification in HMVEC lysates. HMVEC were treated for 24 hrs with 
NAG/Lac (2.5mg/ml) or SR (2.5mg/ml). 
C) Claudin-5 quantification in HMVEC lysates. The cells were treated for 24 hrs with 
NAG/Lac (2.5 mg/ml) or SR (2.5mg/ml).   
